Clinical trials: Prostaglandins
Glaucoma, Ocular Hypertension
Preservative-Free Tafluprost (MK-2452) for the Treatment of Open-Angle Glaucoma or Ocular Hypertension (MK-2452-002)
This study will test the hypothesis that preservative-free tafluprost (MK-2452) is non-inferior to preservative-free timolol maleate with respect to the diurnal intraocular pressure (IOP) change from baseline after 4 weeks of…
- Trial name
- NCT01254604
- Testing
- Preservative-Free Tafluprost or vehicle, Preservative-Free Timolol maleate
- Volunteers
- 190 people
- Sponsor
- Merck Sharp & Dohme LLC
Open-Angle Glaucoma, Ocular Hypertension
SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA)
The purpose of this study is to evaluate the additive intraocular pressure (IOP) lowering effect of brinzolamide 1%/brimonidine 0.2% (dosed twice per day (BID)) when added to a prostaglandin analogue (PGA) in subjects with…
- Trial name
- NCT02419508
- Testing
- Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension, Brinz/brim vehicle, Prostaglandin analogue
- Where
- United States
- Volunteers
- 290 people
- Sponsor
- Alcon Research
Open Angle Glaucoma, Ocular Hypertension
Evaluation of Hyperemia With the Use of Ocular Prostaglandin Analogues
This study will evaluate hyperemia and ocular surface tolerability in patients on prostaglandin analogues
- Trial name
- NCT00539526
- Testing
- Bimatoprost 0.03%, travoprost 0.004%, latanoprost 0.005% eye drops
- Where
- United States
- Volunteers
- 106 people
- Sponsor
- Allergan
Post-Partum Hemorrhage
Fibrinogen in Haemorrhage of Delivery
The purpose of the study is to assess the benefits of a therapeutic strategy that associates an early administration of human fibrinogen concentrate in the management of PPH on the reduction of bleeding after the initiation of…
- Trial name
- FIDEL (NCT02155725)
- Testing
- Human Fibrinogen concentrate
- Where
- 31 sites in France, Martinique
- Volunteers
- 448 people
- Sponsor
- Laboratoire français de Fractionnement et de Biotechnologies
Type 2 Diabetes Mellitus
A Study to Evaluate the Effects of ER Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites (0524A-079)(COMPLETED)
The purpose of this study is to evaluate the potential effects of ER niacin/laropiprant, ER niacin, laropiprant, and placebo over the course of seven days on urinary levels of a specific metabolite (which is a marker of in vivo…
- Trial name
- NCT00618995
- Testing
- Comparator: ER niacin (+) laropiprant, Comparator: ER niacin, Comparator: laropiprant
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Ocular Hypertension, Open Angle Glaucoma
Effect of SIMBRINZA® Suspension as an Added Therapy to a Prostaglandin Analogue
The purpose of this study is to demonstrate the additive effect of brinzolamide 1%/brimonidine 0.2% (SIMBRINZA® suspension) in subjects with either open angle glaucoma or ocular hypertension who are currently on a prostaglandin…
- Trial name
- NCT01937312
- Testing
- Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension, Vehicle, Prostaglandin analogue
- Volunteers
- 282 people
- Sponsor
- Alcon Research
Reducing Time to Vaginal Delivery, Cervical Ripening
Efficacy & Safety Study Comparing Misoprostol Vaginal Insert (MVI) Versus Dinoprostone Vaginal Insert (DVI) for Reducing Time to Vaginal Delivery
The purpose of this study is to determine whether the Misoprostol Vaginal Insert (MVI) 200 microgram (mcg) can decrease the time to vaginal delivery compared to the Dinoprostone Vaginal Insert (DVI) 10 milligram (mg) in pregnant…
- Conditions
- Reducing Time to Vaginal Delivery, Cervical Ripening, Induction of Labor
- Trial name
- EXPEDITE (NCT01127581)
- Testing
- MVI 200, Dinoprostone Vaginal Insert (DVI)
- Where
- 34 sites in United States
- Volunteers
- 1,358 people
- Sponsor
- Ferring Pharmaceuticals
Peripheral Arterial Occlusive Disease
Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV
The study is to confirmatorily show a superior effect of Alprostadil compared to placebo on the rate of complete healing of ischemic necroses and ulcerations as well as on the frequency and height of major amputations in patients…
- Trial name
- ESPECIAL (NCT00596752)
- Testing
- Alprostadil
- Where
- 78 sites in Czechia, Germany and 4 more
- Volunteers
- 840 people
- Sponsor
- UCB BIOSCIENCES GmbH
Glaucoma, Open-Angle, Ocular Hypertension
Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension
This study evaluated the ocular surface tolerability of the prostaglandin analogues bimatoprost ophthalmic solution 0.01% (Lumigan® 0.01%), travoprost ophthalmic solution 0.004% (Travatan Z®) and latanoprost ophthalmic solution…
- Trial name
- NCT01253902
- Testing
- bimatoprost ophthalmic solution 0.01%, travoprost ophthalmic solution 0.004%, latanoprost ophthalmic solution 0.005%
- Where
- 2 sites in United States, Canada
- Volunteers
- 164 people
- Sponsor
- Allergan
Inflammation
Efficacy of Ketorolac 0.4% in Prostaglandin Suppression
A pilot study to evaluate the extent of PGE2 inhibition (mean aqueous values) by Ketorolac 0.04% following peripheral iridotomy
- Trial name
- NCT00791323
- Testing
- Ketorolac 0.4%, Lubricating Eye Drop
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Allergan
Stage II Peripheral Arterial Occlusive Disease, Intermittent Claudication Fontaine Stage II PAOD
Prostaglandin E1 in Outpatients With Intermittent Claudication
Investigate, under outpatient conditions, both the effect of 4 weeks of daily treatment with Prostaglandin E1 and that of 4 weeks of interval treatment (two infusions per week) on the pain-free walking distance in patients with…
- Trial name
- NCT01263925
- Testing
- Alprostadil (Prostaglandin E1), Pentoxifylline
- Where
- 36 sites in Germany
- Volunteers
- 561 people
- Sponsor
- UCB Pharma
Hypercholesterolemia
A Study to Evaluate the Effects of Extended Release (ER) Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites in Subjects With High Cholesterol (0524A-075)(COMPLETED)
The purpose of this study is to evaluate the potential effects of ER niacin/laropiprant, ER niacin, laropiprant, and placebo over the course of seven days on urinary levels of a metabolite of thromboxane A2 (TxA2), as a marker of…
- Trial name
- NCT00769132
- Testing
- Comparator: niacin + laropiprant, Comparator: niacin, Comparator: laropiprant
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Pulmonary Arterial Hypertension
Epoprostenol for Injection in Pulmonary Arterial Hypertension - Extension of AC-066A401
This is an open-label, non-randomized extension to study AC-066A401. The study will assess safety and tolerability of ACT-385781A and Flolan (epoprostenol sodium) while providing a means for continuing treatment after ending…
- Trial name
- EPITOME-1 Ext (NCT01105117)
- Testing
- ACT-385781A (Actelion Epoprostenol), Flolan®
- Where
- 7 sites in United States
- Volunteers
- 2 people
- Sponsor
- Actelion
Macular Degeneration
Alprostadil in Maculopathy Study (AIMS)
Evaluation of efficacy of alprostadil (prostaglandin E1) for treatment of patients suffering from dry age-related macula degeneration
- Trial name
- NCT00619229
- Testing
- Alprostadil (prostaglandin E1)
- Where
- 6 sites in Germany
- Volunteers
- 37 people
- Sponsor
- UCB Pharma
Ocular Hypertension, Open Angle Glaucoma
Effect of SIMBRINZA® Suspension as an Added Therapy to TRAVATAN Z®
The purpose of this study is to demonstrate the additive effect of brinzolamide 1%/brimonidine 0.2% (SIMBRINZA® suspension) in subjects with either open angle glaucoma or ocular hypertension who are currently on a prostaglandin…
- Trial name
- NCT01937299
- Testing
- Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension, Vehicle, Travoprost 0.004% ophthalmic solution
- Volunteers
- 307 people
- Sponsor
- Alcon Research
Pulmonary Arterial Hypertension
Epoprostenol for Injection in Pulmonary Arterial Hypertension
This is a prospective, multi-center, open-label, randomized, Phase IV exploratory study comparing safety, tolerability, pharmacokinetics, and effectiveness of ACT-385781A and Flolan (epoprostenol sodium) in patients with…
- Trial name
- EPITOME-1 (NCT01105091)
- Testing
- ACT-385781A (Actelion Epoprostenol), Flolan®
- Volunteers
- 30 people
- Sponsor
- Actelion
Glaucoma, Ocular Hypertension
Safety and Efficacy of Adding AZARGA® Adjunctive to Prostaglandin Therapy
The purpose of this study was to evaluate the safety and efficacy of adding AZARGA® as a single agent to prostaglandin monotherapy in patients with either ocular hypertension or primary open-angle glaucoma.
- Trial name
- NCT01263444
- Testing
- Brinzolamide 1% / timolol 0.5% Fixed Combination, Habitual prostaglandin monotherapy
- Volunteers
- 47 people
- Sponsor
- Alcon Research
Glaucoma
Safety and Tolerability of the Ophthalmic Solution PRO-179 Compared With Travatan®
Phase I clinical study, to evaluate the safety and tolerability of the ophthalmic solution PRO-179 compared with Travatan®, on the ocular surface of clinically healthy subjects.
- Trial name
- PRO-179/I (NCT03965052)
- Testing
- PRO 179, Travatan 0.004 % Ophthalmic Solution
- Where
- Mexico
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Laboratorios Sophia S.A de C.V.
Chronic Obstructive Pulmonary Disease
A Proof-of-mechanism Study of Multiple, Oral Doses of Fevipiprant (QAW039) in COPD Patients With Eosinophilia
This was an exploratory, randomized, subject- and investigator-blind, placebo-controlled, parallel group, proof-of-mechanism study of multiple oral doses of fevipiprant (QAW039) in chronic obstructive pulmonary disease (COPD)…
- Trial name
- NCT03810183
- Testing
- QAW039
- Where
- 4 sites in Germany, United Kingdom
- Volunteers
- 9 people
- Sponsor
- Novartis Pharmaceuticals
Glaucoma
A Comparison of Azopt Versus Placebo Added to Xalatan in Patients With Elevated Intraocular Pressure (IOP) on a Prostaglandin
The purpose of this study was to assess the efficacy of adding Azopt dosed three times a day to Xalatan as compared to that of adding placebo to Xalatan in patients with elevated intraocular pressure.
- Trial name
- NCT00759941
- Testing
- Brinzolamide 1% ophthalmic solution (Azopt), Latanoprost 0.005% ophthalmic solution (Xalatan)
- Where
- United States
- Volunteers
- 86 people
- Sponsor
- Alcon Research